Caplin Point Lab

₹1286.1 11.9 | 0.9%

WEBSITE BSE:524742 NSE : CAPLIN POINT 10 May, 16:01

Market Cap ₹9767 Cr.

Stock P/E 22.3

P/B 4.5

Current Price ₹1286.1

Book Value ₹ 288.8

Face Value 2

52W High ₹1617.8

Dividend Yield 0.35%

52W Low ₹ 676.7

Edit Ratio

Caplin Point Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Caplin Point Laboratories Ltd is a pharmaceutical company. It's product segments are Non-steroidal anti-inflammatory drugs (NSAIDS), Ophthalmics, Antibiotics, Pain Management and Anti-ulcers. The Company offers a number of products, including Tablets, Liquid Orals, Capsule, Inhalers, intravenous (IV) Infusion, Lyophilized Products, Softgel Capsules, Suppositories and Ovules, Powder for Injection, Dry syrup, Topicals, Liquid Injections, Branded Products, Dermo Cosmetics and Other Products. It additionally manufactures a variety of ointments, lotions, and gels. The Company has presence in Latin American international locations of Guatemala, Honduras, Nicaragua, El Salvador, Ecuador, Honduras, Venezuela and Dominican Republic. The Company's production facilities are located in Suthukeny village, Puducherry; Gummidipoondi Taluk, Tamil Nadu, and Baddi, Himachal Pradesh. Its R&D units are located in Gummidipoondi Taluk, Tamil Nadu.

Caplin Point Lab Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Caplin Point Lab Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	304	326	339	346	359	372	389	395	410	436
Other Income	8	10	12	14	16	14	11	12	20	17
Total Income	312	336	351	360	376	386	401	407	430	453
Total Expenditure	202	225	239	244	253	263	265	269	273	293
Operating Profit	110	111	111	116	122	124	135	139	158	159
Interest	0	0	0	0	0	0	0	0	0	0
Depreciation	12	12	11	11	11	11	11	11	12	14
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	98	99	100	105	110	112	124	127	146	145
Provision for Tax	21	19	19	19	18	14	23	23	30	26
Profit After Tax	77	79	81	86	92	97	101	104	116	120
Adjustments	-2	-4	-2	-1	-0	0	1	-1	-1	-3
Profit After Adjustments	75	75	79	85	92	97	102	103	115	117
Adjusted Earnings Per Share	9.9	9.9	10.4	11.2	12.1	12.8	13.5	13.6	15.1	15.4

Caplin Point Lab Profit & Loss

#(Fig in Cr.)	Jun 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	127	173	252	239	402	540	649	863	1061	1269	1467	1630
Other Income	2	4	3	4	10	13	19	41	28	39	57	60
Total Income	129	177	255	242	412	553	668	905	1089	1308	1523	1691
Total Expenditure	105	137	192	175	277	345	417	603	737	875	1026	1100
Operating Profit	24	40	63	68	135	208	251	301	352	433	497	591
Interest	1	1	1	0	1	1	1	0	2	1	1	0
Depreciation	2	4	8	7	13	19	23	32	37	47	45	48
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	22	36	53	60	121	188	227	269	314	386	451	542
Provision for Tax	8	10	12	14	25	44	50	54	62	77	74	102
Profit After Tax	14	26	41	46	96	145	177	215	251	308	377	441
Adjustments	-0	-0	-0	-0	0	0	0	-0	-9	-9	-1	-4
Profit After Adjustments	14	26	41	46	96	145	177	215	242	300	376	437
Adjusted Earnings Per Share	1.9	3.4	5.4	6.1	12.7	19.2	23.3	28.4	32	39.6	49.6	57.6

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	16%	19%	22%	28%
Operating Profit CAGR	15%	18%	19%	35%
PAT CAGR	22%	21%	21%	39%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	88%	30%	31%	43%
ROE Average	24%	25%	28%	40%
ROCE Average	27%	28%	33%	50%

Caplin Point Lab Balance Sheet

#(Fig in Cr.)	Jun 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	43	62	93	128	225	364	633	948	1186	1484	1880
Minority's Interest	0	0	0	0	0	0	0	9	18	26	27
Borrowings	3	2	1	1	0	0	0	0	0	0	0
Other Non-Current Liabilities	5	8	10	13	19	28	23	25	17	13	2
Total Current Liabilities	83	108	125	125	113	109	86	144	143	208	268
Total Liabilities	135	180	229	267	358	500	743	1126	1364	1730	2178
Fixed Assets	33	102	113	144	152	169	227	273	305	287	280
Other Non-Current Assets	64	29	34	4	27	27	22	31	44	146	343
Total Current Assets	39	49	82	119	179	304	494	823	1015	1298	1554
Total Assets	135	180	229	267	358	500	743	1126	1364	1730	2178

Caplin Point Lab Cash Flow

#(Fig in Cr.)	Jun 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	32	17	27	45	67	91	77	151	221	232	151
Cash Flow from Operating Activities	32	60	50	42	68	66	83	45	269	337	271
Cash Flow from Investing Activities	-45	-44	-23	-6	-36	-69	-100	-55	-29	-377	-218
Cash Flow from Financing Activities	-1	-6	-9	-14	-7	-12	90	80	-24	-41	-28
Net Cash Inflow / Outflow	-15	10	19	23	25	-14	73	70	215	-81	26
Closing Cash & Cash Equivalent	17	27	45	68	91	77	151	221	436	151	178

Caplin Point Lab Ratios

#	Jun 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	1.85	3.42	5.43	6.06	12.65	19.15	23.34	28.42	32.03	39.56	49.57
CEPS(Rs)	2.06	3.9	6.55	7.05	14.4	21.64	26.44	32.61	38.12	46.88	55.6
DPS(Rs)	0.5	0.8	1	1.2	1.5	2	2.2	2.5	3	4	4.5
Book NAV/Share(Rs)	5.22	7.68	11.84	16.25	29.73	47.69	78.03	114.21	144.94	183.89	235.91
Core EBITDA Margin(%)	17.54	20.9	23.71	26.9	31.07	36.18	35.74	30.13	30.55	31.08	30.03
EBIT Margin(%)	17.98	21.01	21.59	25.3	30.24	35.01	35.06	31.25	29.7	30.45	30.83
Pre Tax Margin(%)	17.37	20.61	21.2	25.16	30.11	34.9	34.97	31.22	29.55	30.39	30.77
PAT Margin (%)	11	14.98	16.33	19.17	23.78	26.79	27.22	24.92	23.69	24.3	25.7
Cash Profit Margin (%)	12.21	17.02	19.66	22.3	27.09	30.31	30.83	28.58	27.17	27.99	28.77
ROA(%)	11.59	16.48	20.12	18.46	30.54	33.68	28.41	23.02	20.2	19.94	19.29
ROE(%)	40.49	53.24	55.78	43.13	54.97	49.43	37.14	29.58	25.65	24.77	23.68
ROCE(%)	56.69	68.99	71.11	55.41	69.03	64.08	45.59	33.35	28.82	28.77	26.85
Receivable days	11.66	1	4.17	10.4	18.62	53.72	80.37	82.19	87.41	85.74	88.48
Inventory Days	24.06	21.31	17	24.83	18.68	17.16	18.54	58.28	71.75	58.42	64.15
Payable days	101.34	101.65	98.32	146.5	132.54	132.42	97.76	55.04	59.05	80.02	88.14
PER(x)	5.08	12.94	34.23	33.39	30.68	29.92	17.24	9.93	12.62	17.19	12.04
Price/Book(x)	1.8	5.77	15.7	12.45	13.06	12.02	5.16	2.47	2.79	3.7	2.53
Dividend Yield(%)	5.32	1.81	0.54	0.59	0.39	0.35	0.55	0.89	0.74	0.59	0.75
EV/Net Sales(x)	0.46	1.8	5.41	6.12	7.07	7.88	4.51	2.34	2.55	3.75	2.8
EV/Core EBITDA(x)	2.41	7.79	21.7	21.54	21.08	20.45	11.66	6.71	7.7	11	8.28
Net Sales Growth(%)	18.48	36.26	45.46	-5.18	68.25	34.41	20.16	33.07	22.95	19.61	15.54
EBIT Growth(%)	84.31	58.76	49.44	11.1	101.14	55.59	20.36	18.61	16.84	22.62	16.97
PAT Growth(%)	74.61	84.95	58.59	11.29	108.66	51.45	22.07	21.82	16.9	22.68	22.22
EPS Growth(%)	74.65	84.85	58.76	11.52	108.85	51.38	21.9	21.76	12.67	23.52	25.32
Debt/Equity(x)	0.12	0.06	0.02	0.02	0	0	0	0.04	0.01	0	0
Current Ratio(x)	0.47	0.45	0.66	0.95	1.58	2.8	5.73	5.7	7.1	6.25	5.8
Quick Ratio(x)	0.34	0.36	0.55	0.8	1.38	2.54	5.3	4.05	5.85	5.15	4.72
Interest Cover(x)	29.73	53.29	56.11	179.35	235.08	309.72	391.22	843.86	198.25	552.17	579.65
Total Debt/Mcap(x)	0.07	0.01	0	0	0	0	0	0.02	0.01	0	0

Caplin Point Lab Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	68.91	68.89	68.88	68.88	68.8	70.66	70.63	70.63	70.62	70.62
FII	2.11	2.07	2.03	2.15	2.24	2.36	2.69	3.07	2.85	3.32
DII	1.22	1.25	1.12	1.12	1.12	0.65	0.26	0.22	0.43	1.1
Public	27.76	27.78	27.97	27.85	27.84	26.34	26.42	26.08	26.1	24.95
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	5.22	5.22	5.22	5.22	5.22	5.36	5.36	5.36	5.36	5.36
FII	0.16	0.16	0.15	0.16	0.17	0.18	0.2	0.23	0.22	0.25
DII	0.09	0.09	0.09	0.08	0.08	0.05	0.02	0.02	0.03	0.08
Public	2.1	2.11	2.12	2.11	2.11	2	2.01	1.98	1.98	1.89
Others	0	0	0	0	0	0	0	0	0	0
Total	7.58	7.58	7.58	7.58	7.59	7.59	7.59	7.59	7.59	7.59

Pros

Company has delivered good profit growth of 21% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 25%
Company is almost debt free.

Cons

Debtor days have increased from 80.02 to 88.14days.
Stock is trading at 4.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Caplin Point Lab News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Caplin Point Lab

Add Watchlist

Caplin Point Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Caplin Point Lab Share Price

Alert Data

Quarterly Price

Peer Comparison

Caplin Point Lab Quarterly Results

Caplin Point Lab Profit & Loss

Growth Rates

Caplin Point Lab Balance Sheet

Caplin Point Lab Cash Flow

Caplin Point Lab Ratios

Caplin Point Lab Shareholding Pattern

Caplin Point Lab News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!